BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 25843002)

  • 1. Cancer cell-autonomous TRAIL-R signaling promotes KRAS-driven cancer progression, invasion, and metastasis.
    von Karstedt S; Conti A; Nobis M; Montinaro A; Hartwig T; Lemke J; Legler K; Annewanter F; Campbell AD; Taraborrelli L; Grosse-Wilde A; Coy JF; El-Bahrawy MA; Bergmann F; Koschny R; Werner J; Ganten TM; Schweiger T; Hoetzenecker K; Kenessey I; Hegedüs B; Bergmann M; Hauser C; Egberts JH; Becker T; Röcken C; Kalthoff H; Trauzold A; Anderson KI; Sansom OJ; Walczak H
    Cancer Cell; 2015 Apr; 27(4):561-73. PubMed ID: 25843002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SOX9 activity is induced by oncogenic Kras to affect MDC1 and MCMs expression in pancreatic cancer.
    Zhou H; Qin Y; Ji S; Ling J; Fu J; Zhuang Z; Fan X; Song L; Yu X; Chiao PJ
    Oncogene; 2018 Feb; 37(7):912-923. PubMed ID: 29059173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nuclear death receptor TRAIL-R2 inhibits maturation of let-7 and promotes proliferation of pancreatic and other tumor cells.
    Haselmann V; Kurz A; Bertsch U; Hübner S; Olempska-Müller M; Fritsch J; Häsler R; Pickl A; Fritsche H; Annewanter F; Engler C; Fleig B; Bernt A; Röder C; Schmidt H; Gelhaus C; Hauser C; Egberts JH; Heneweer C; Rohde AM; Böger C; Knippschild U; Röcken C; Adam D; Walczak H; Schütze S; Janssen O; Wulczyn FG; Wajant H; Kalthoff H; Trauzold A
    Gastroenterology; 2014 Jan; 146(1):278-90. PubMed ID: 24120475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
    Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
    Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of heterozygosity for Kras
    Ma Y; Li Y; Ling S; Li X; Kong B; Hu M; Huang P
    Biochem Biophys Res Commun; 2020 Jun; 526(4):880-888. PubMed ID: 32279996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
    Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
    Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CXCR2 signaling regulates KRAS(G¹²D)-induced autocrine growth of pancreatic cancer.
    Purohit A; Varney M; Rachagani S; Ouellette MM; Batra SK; Singh RK
    Oncotarget; 2016 Feb; 7(6):7280-96. PubMed ID: 26771140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of the transcriptional repressor TGIF1 results in enhanced Kras-driven development of pancreatic cancer.
    Weng CC; Hsieh MJ; Wu CC; Lin YC; Shan YS; Hung WC; Chen LT; Cheng KH
    Mol Cancer; 2019 May; 18(1):96. PubMed ID: 31109321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of the wild-type KRAS allele promotes pancreatic cancer progression through functional activation of YAP1.
    Yan H; Yu CC; Fine SA; Youssof AL; Yang YR; Yan J; Karg DC; Cheung EC; Friedman RA; Ying H; Chen EI; Luo J; Miao Y; Qiu W; Su GH
    Oncogene; 2021 Dec; 40(50):6759-6771. PubMed ID: 34663879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PIN1 Maintains Redox Balance via the c-Myc/NRF2 Axis to Counteract Kras-Induced Mitochondrial Respiratory Injury in Pancreatic Cancer Cells.
    Liang C; Shi S; Liu M; Qin Y; Meng Q; Hua J; Ji S; Zhang Y; Yang J; Xu J; Ni Q; Li M; Yu X
    Cancer Res; 2019 Jan; 79(1):133-145. PubMed ID: 30355620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncogenic
    Kim MP; Li X; Deng J; Zhang Y; Dai B; Allton KL; Hughes TG; Siangco C; Augustine JJ; Kang Y; McDaniel JM; Xiong S; Koay EJ; McAllister F; Bristow CA; Heffernan TP; Maitra A; Liu B; Barton MC; Wasylishen AR; Fleming JB; Lozano G
    Cancer Discov; 2021 Aug; 11(8):2094-2111. PubMed ID: 33839689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of Pten and Activation of Kras Synergistically Induce Formation of Intraductal Papillary Mucinous Neoplasia From Pancreatic Ductal Cells in Mice.
    Kopp JL; Dubois CL; Schaeffer DF; Samani A; Taghizadeh F; Cowan RW; Rhim AD; Stiles BL; Valasek M; Sander M
    Gastroenterology; 2018 Apr; 154(5):1509-1523.e5. PubMed ID: 29273451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-802 Suppresses Acinar-to-Ductal Reprogramming During Early Pancreatitis and Pancreatic Carcinogenesis.
    Ge W; Goga A; He Y; Silva PN; Hirt CK; Herrmanns K; Guccini I; Godbersen S; Schwank G; Stoffel M
    Gastroenterology; 2022 Jan; 162(1):269-284. PubMed ID: 34547282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
    McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
    Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disruption of p16 and activation of Kras in pancreas increase ductal adenocarcinoma formation and metastasis in vivo.
    Qiu W; Sahin F; Iacobuzio-Donahue CA; Garcia-Carracedo D; Wang WM; Kuo CY; Chen D; Arking DE; Lowy AM; Hruban RH; Remotti HE; Su GH
    Oncotarget; 2011 Nov; 2(11):862-73. PubMed ID: 22113502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long non-coding RNA LOC389641 promotes progression of pancreatic ductal adenocarcinoma and increases cell invasion by regulating E-cadherin in a TNFRSF10A-related manner.
    Zheng S; Chen H; Wang Y; Gao W; Fu Z; Zhou Q; Jiang Y; Lin Q; Tan L; Ye H; Zhao X; Luo Y; Li G; Ye L; Liu Y; Li W; Li Z; Chen R
    Cancer Lett; 2016 Feb; 371(2):354-65. PubMed ID: 26708505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KRAS/NF-κB/YY1/miR-489 Signaling Axis Controls Pancreatic Cancer Metastasis.
    Yuan P; He XH; Rong YF; Cao J; Li Y; Hu YP; Liu Y; Li D; Lou W; Liu MF
    Cancer Res; 2017 Jan; 77(1):100-111. PubMed ID: 27793842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncogenic KRAS Induces NIX-Mediated Mitophagy to Promote Pancreatic Cancer.
    Humpton TJ; Alagesan B; DeNicola GM; Lu D; Yordanov GN; Leonhardt CS; Yao MA; Alagesan P; Zaatari MN; Park Y; Skepper JN; Macleod KF; Perez-Mancera PA; Murphy MP; Evan GI; Vousden KH; Tuveson DA
    Cancer Discov; 2019 Sep; 9(9):1268-1287. PubMed ID: 31263025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transgelin-2 is a novel target of KRAS-ERK signaling involved in the development of pancreatic cancer.
    Sun Y; Peng W; He W; Luo M; Chang G; Shen J; Zhao X; Hu Y
    J Exp Clin Cancer Res; 2018 Jul; 37(1):166. PubMed ID: 30041673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
    Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
    Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.